Mentioned in

References in periodicals archive

Agostoni, "Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment," Archives of Internal Medicine, vol.

Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema

Hypotensive reactions to white cell-reduced plasma in a patient undergoing angiotensin-converting enzyme inhibitor therapy.

The development of a novel molecular assay examining the role of aminopeptidase P polymorphisms in acute hypotensive transfusion reactions

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled clinical trial.

Since the publication of the South African Hypertension Guidelines in 2006 several landmark clinical trials have been published or presented that have far-reaching implications for the way we treat patients with hypertension. In addition, the review of a recent study that had major impact on nephrological practice has been seriously questioned

Cardiorenal protective effects of yearlong antihypertensive therapy with a angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rat.

Attenuating development of cardiovascular hypertrophy with hydrolysate of chicken leg bone protein in spontaneously hypertensive rats

Examples of such differences that have already been observed in trials include the finding that hypertensive black patients do not respond as well to [beta]-blockers or angiotensin-converting enzyme inhibitors. Black patients with hepatitic C also have not responded as well to treatment with interferon-a, compared with other racial groups in clinical trials.

Race, ethnicity categories proposed for drug trials. (FDA Draft Document)

"Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 states." Arch Intern Med.

Customized Clinical Case Management for Chronically Ill Patients

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure.

Use of angiotensin-converting enzyme inhibitors in elderly patients with heart failure

Angiotensin-converting enzyme inhibitors (ACEIs) are effective antihypertensive drugs, but use of ACEIs during the second and third trimesters of pregnancy has been associated with a pattern of defects known as ACEI fetopathy.

Postmarketing surveillance for angiotensin-coverting enzyme inhibitor use during the first trimester of pregnancy - United States, Canada, and Israel, 1987-1995

As such, it would be prescribed only if symptoms persisted after the use of such drugs as angiotensin-converting enzyme inhibitors and beta blockers, which reduce the risk of hospitalization and death.

Stubborn digitalis debate continues

The researchers note that the patient was initially treated with diuretics, ?-blockers, and angiotensin-converting enzyme inhibitors. Six months later, when he was still symptomatic, the patient was determined to have met the criteria for idiopathic inflammatory dilated cardiomyopathy, and initiated treatment with anakinra.

Rapid Improvement of Dilated Cardiomyopathy With Anakinra; Patient's clinical symptoms related to heart failure improved markedly within two weeks of treatment

CREDENCE, the first dedicated renal outcomes trial in patients with CKD and T2D on the background of standard of care, including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, enrolled approximately 4,400 patients with T2D, estimated glomerular filtration rate >=30 to 300 to <=5,000 mg/g).

Phase 3 Renal Outcomes Trial of Invokana Stopped Early Based on Positive Efficacy